- The company recently completed clinical trials for its acute pain formulation, CTL-X, which is the most advanced product in the Veritas pipeline
- Veritas Pharma works in two directions to put together effective cannabis-based treatments for various medical conditions
- With the help of R&D partner Cannevert Therapeutics, Veritas is developing solutions for various additional issues like chronic pain and sleep disorders
Pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is on a mission to develop the most effective proprietary cannabis strains and products for the treatment of various medical conditions. The company focuses on providing both physicians and patients with conclusive evidence for the recommendation of medical marijuana.
In the spring of 2019, Veritas announced the results of its product clinical trials in support of the company’s commitment to developing the most effective products (http://cnw.fm/nOsU5). The cannabis treatment clinical trial (randomized, double-blinded, cross-over) tested the effectiveness of the company’s vaporized CTL-X acute pain product. Studies were carried out following GMP standards over the course of three months. The results provide real scientific evidence of the use of cannabis for medical purposes and, more specifically, for the treatment of acute pain.
“We believe that for millions of people suffering from acute pain vaporized cannabis can potentially reduce the need for other medications, including opioids. From results of this study, clinicians will have a better understanding for specific dosage and delivery of cannabis for acute pain,” Veritas Medical Director Dr. Scott Alexander stated in a news release.
Veritas’ innovative research and development approach aims to solve the critical need for scientific research to support claims about the effectiveness of cannabis-based treatments. Through its research and development subsidiary, Cannevert Therapeutics Ltd., Veritas is developing innovative products for the treatment of various medical conditions like chronic and acute pain, sleep disorders and palliative care.
Cannevert has screened numerous cannabis strains to pinpoint their potential in treating chronic pain and reducing the need for opioid administration. Acute pain treatment CTL-X is the most advanced product in the Veritas pipeline and therefore the focus of its clinical trial efforts.
Veritas is also concerned with sleep disorders and the growing prominence of the conditions. Studies show that Americans are now getting one to two hours less sleep than previous generations (http://cnw.fm/vAx5v). In 1942, only 11 percent of Americans slept six hours or less per night. By 2013, the number had increased to 40 percent of the adult population, the American Association of Retired Persons (AARP) reported.
Through its research, Veritas is attempting to identify cannabis as a reliable solution to this growing problem. There is some anecdotal evidence, and Cannevert is working to develop biological assays to identify the most effective strain for the treatment of insomnia, parasomnia, chronic fatigue syndrome and others.
Based at the University of British Columbia, Cannevert has brought together a team of pharmacologists, chemists and anesthetists who have substantial prior experience in drug development. Through the partnership, Veritas gains the technical ability to achieve its effective treatment development vision.
For more information, visit the company’s website at www.VeritasPharmaInc.com
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com